Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221

Oncotarget
N FalkenbergM Aubele

Abstract

miR-221/-222 and components of the urokinase-type plasminogen activator system (uPAS) are associated with metastasis and poor prognosis in breast cancer, including the triple-negative subtype (TNBC). Modification of components of uPAS and involved miRNAs may contribute to targeted therapy for breast cancer patients. miR-221-/-222-overexpressing or miR-221-depleted cells were employed for qRT-PCR and Western blots to show associations of uPAR with miR-221/-222. To substantiate direct targeting of miR-221/-222 within 3' UTR of the uPAR isoform 2, in silico analysesand in vitro assays were conducted. Significant associations between miR-221 and uPAR isoform 2 expressions were observed at the mRNA and protein levels in breast cancer cells representing TNBC. For the first time, the uPAR isoform 2 was demonstrated as direct target for miR-221/-222. Inhibition of miR-221 reduced uPAR protein expression and expression of the tumor cell invasion markers vimentin and RHOC. These results demonstrate a direct and positive regulation of the secreted uPAR isoform 2 by miR-221, increasing its protein expression, a prerequisite for malignancy, while the other uPAR isoforms (1, 3 and 4) are indirectly regulated through miR-10b and miR-221/-222....Continue Reading

References

Nov 1, 1993·Biochemical Society Transactions·U Bayraktutan, P Jones
Dec 6, 2002·The American Journal of Pathology·Connie MyersNancy Boudreau
Jul 14, 2005·Molecular and Cellular Biochemistry·Sreerama Shetty
Jun 6, 2007·Molecular and Cellular Biology·Sreerama ShettyRashmi S Shetty
Jan 17, 2008·Nature Reviews. Genetics·Witold FilipowiczNahum Sonenberg
Aug 19, 2008·The Journal of Biological Chemistry·Tyler E MillerSarmila Majumder
Jun 19, 2009·International Journal of Cancer. Journal International Du Cancer·Takashi SasayamaEiji Kohmura
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura GramantieriMassimo Negrini
Sep 4, 2009·Breast Cancer Research and Treatment·Lauren A LicataJudith Clancy Keen
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marilena V Iorio, Carlo M Croce
Sep 4, 2010·Molecular Cancer·Chun-Zhi ZhangChun-Sheng Kang
Jan 29, 2011·Cell Cycle·Jelena RadojicicEfstathios N Stathopoulos
Nov 11, 2011·Wiley Interdisciplinary Reviews. RNA·Shobha Vasudevan
Dec 12, 2012·Radiation Oncology·Nataša AnastasovMichael J Atkinson
Jun 3, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yuan LiZuoren Yu

❮ Previous
Next ❯

Citations

Dec 13, 2017·Oncotarget·Manjula NakkaUNKNOWN TARGET osteosarcoma consortium
Jun 28, 2018·Breast Cancer Research and Treatment·Edna Ayerim Mandujano-TinocoVilma Maldonado
Dec 18, 2020·Frontiers in Oncology·Simona Ruxandra VolovatIolanda Augustin

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
transfections
Assay
PCR

Software Mentioned

CLUSTALW2
CLUSTLW2

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

© 2021 Meta ULC. All rights reserved